When was Apellis Pharmaceuticals founded?

Apellis Pharmaceuticals was founded in 2008 and raised its 1st funding round within a year of its incorporation.

Where is Apellis Pharmaceuticals located?

Apellis Pharmaceuticals is headquartered in Crestwood, United States.

Who is the current CEO of Apellis Pharmaceuticals?

Cedric Francois of Apellis Pharmaceuticals. They have also founded 1 company.

How many employees does Apellis Pharmaceuticals have?

As of Aug 31, 2026, the latest employee count at Apellis Pharmaceuticals is 536.

Is Apellis Pharmaceuticals a funded company?

Apellis Pharmaceuticals is a funded company, having raised a total of $213M across 13 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jul 01, 2008.

How much is Apellis Pharmaceuticals worth?

The last known valuation of Apellis Pharmaceuticals was $***** as of Apr 02, 2026.

When was the latest funding round of Apellis Pharmaceuticals?

Apellis Pharmaceuticals' latest funding was a $***** Post IPO round on May 07, 2020, with participation from 0 investor.

What is the annual revenue of Apellis Pharmaceuticals?

Annual revenue of Apellis Pharmaceuticals is more than $1B as on Dec 31, 2025

Where does Apellis Pharmaceuticals rank among its competitors?

Apellis Pharmaceuticals ranks 53rd amongst 3249 active competitors, of which 1078 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Apellis Pharmaceuticals?

Apellis Pharmaceuticals' top competitors include Jazz Pharmaceuticals, BridgeBio and BeiGene. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Apellis Pharmaceuticals - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics for the treatment of rare diseases. The company is developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. The company develops programs across ophthalmology, nephrology, hematology, and neurology.

Website: apellis.com
Social

Key Metrics

Founded Year

2008

Location

Crestwood, United States

Stage

Acquired

Total Funding

$213M in 13 rounds

Latest Funding Round

Post IPO, May 07, 2020, $*****

Last Known Valuation

$***** as on Apr 02, 2026

Investors

Morningside & 22 more

Ranked

53^rd among 3249 active competitors

Annual Revenue

$1B+ as on Dec 31, 2025

Employee Count

536 as on Aug 31, 2026

Similar Companies

BridgeBio & 1094 more

Exit Details

Acquired by Biogen (Mar 31, 2026)

View Apellis Pharmaceuticals' full profile

Apellis Pharmaceuticals is associated with 6 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Apellis Pharmaceuticals, Inc. CIN: 214632499 , United States, Active	Jul 17, 2023	-	-	-
Apellis Pharmaceuticals, Inc. CIN: 20181328397 , United States, Active	Apr 23, 2018	$1 - $1M (As on Jun 09, 2015)	-	-
Apellis Pharmaceuticals, Inc. CIN: 32069752759 , United States, Active	Feb 13, 2019	-	-	-
Apellis Estonia OÜ CIN: 14858554 , Estonia, Active	Nov 27, 2019	€0 - €1M (As on Dec 31, 2022)	1 (As on Mar 31, 2022)
APELLIS PHARMACEUTICALS, INC. CIN: 1492422 , United States, Active	Sep 24, 2009	$1B+ (As on Dec 31, 2025)	-	-
APELLIS PHARMACEUTICALS CIN: 271537290 , United States, Active		-	615 (As on Dec 31, 2024)	-

Apellis Pharmaceuticals got acquired by Biogen on Mar 31, 2026 at an acquisition amount of $*****.

Click here to take a look at Apellis Pharmaceuticals's acquisition in detail

Apellis Pharmaceuticals has raised a total funding of $213M over 13 rounds. Its first funding round was on Jul 01, 2008. Apellis Pharmaceuticals has 23 institutional investors.

Here is the list of recent funding rounds of Apellis Pharmaceuticals:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 07, 2020	9375095	Post IPO	5837896	5739000	2251225	4653710
Sep 11, 2019	3458792	Post IPO	8358102	9441222	2185298	3219570
Aug 14, 2017	8988927	Series E	2898545	8163488	Sectoral	Sofinnova Investments & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Apellis Pharmaceuticals's funding rounds and investors

The founders of Apellis Pharmaceuticals are Pascal Deschatelets and Cedric Francois. Cedric Francois is the CEO of Apellis Pharmaceuticals.

Here are the details of Apellis Pharmaceuticals' key team members:

Pascal Deschatelets: Co-Founder of Apellis Pharmaceuticals.
Contact Info: 1 email address
Cedric Francois: Co-Founder & CEO of Apellis Pharmaceuticals and founder of 2 other companies, Revon Systems and Revon Systems.
Contact Info: 1 email address

View details of Apellis Pharmaceuticals's Founder profiles and Board Members

Apellis Pharmaceuticals' employee count trend

Apellis Pharmaceuticals has 536 employees as of Aug 26. Here is Apellis Pharmaceuticals's employee count trend over the years:

Employee count trend for Apellis Pharmaceuticals

Uncover Apellis Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Apellis Pharmaceuticals include Jazz Pharmaceuticals, BridgeBio and BeiGene. Here is the list of Top 10 competitors of Apellis Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
3rd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
4th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
5th	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
6th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
7th	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Seventure Partners ... & 21 others	75/100
8th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
9th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
10th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, T. Rowe Price & 6 others	73/100
53rd	Apellis Pharmaceuticals 2008, Crestwood (United States), Acquired	Developer of therapeutics for the treatment of rare diseases	$213M	Avoro Capital, VenBio & 21 others	66/100